Skip to main content
Equibles
HAE logo

HAE · Haemonetics Corp · Metrics

Track HAE — free

Use HAE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HAE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$121.00 +1.81 (+1.52%)
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$5.42B
Shares
45.50M
Volume · Oct 27 539.65K Avg daily vol (3M) 737.07K

HAE metrics

108 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$119.19
Market cap
$5.42B

Price action

20 metrics
Price change (1W)
+0.4%
Price change (30D)
+12.7%
Price change (3M)
+49.2%
Price change (6M)
+97.1%
Price change (YTD)
+48.7%
Price change (1Y)
+132.5%
Trailing year
Price change (5Y)
+66.5%
52-week high
$122.06
52-week low
$49.44
Change from 52-week high
-2.4%
Change from 52-week low
+141.1%
Annualized volatility
51.7%
Annualized volatility (3M)
52.0%
Beta
0.0
RSI (14D)
64.8
Price vs SMA 50
+9.7%
Price vs SMA 200
+53.1%
Avg volume (3M)
737,071
Relative volume
0.7
Average dollar volume
$76.19M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
45.50M

Valuation

12 metrics
P / E (TTM)
57.6
Trailing earnings · reciprocal yield 1.7%
PEG ratio
20.2
EV / revenue
4.7×
reciprocal yield 21.3%
EV / EBITDA
23.5×
reciprocal yield 4.3%
EV / EBIT
39.6×
reciprocal yield 2.5%
P / sales
4.0×
reciprocal yield 25.1%
P / book
6.4
reciprocal yield 15.5%
FCF yield
5.4%
TTM · current market cap
Buyback yield
—
P / FCF
18.5
reciprocal yield 5.4%
P / operating cash flow
16.4
reciprocal yield 6.1%
Earnings yield
1.8%

Historical valuation

8 metrics
P / E historical average (3Y)
30.2×
reciprocal yield 3.3%
P / E historical average (5Y)
44.3×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
3.4×
reciprocal yield 29.4%
EV / revenue historical average (5Y)
3.7×
reciprocal yield 27.0%
EV / EBIT historical average (3Y)
24.8×
reciprocal yield 4.0%
EV / EBIT historical average (5Y)
34.3×
reciprocal yield 2.9%
EV / EBITDA historical average (3Y)
15.4×
reciprocal yield 6.5%
EV / EBITDA historical average (5Y)
18.0×
reciprocal yield 5.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
59.0%
Operating margin
11.9%
Trailing 12 months
Net margin
7.1%
Gross profit (TTM)
$798.14M
Operating profit (TTM)
$160.32M
Net income (TTM)
$96.29M
Trailing 12 months
Diluted EPS (TTM)
$2.07
FCF margin
21.5%
Effective tax rate
26.2%

Per share

11 metrics
Revenue per diluted share (TTM)
$28.97
Gross profit per diluted share (TTM)
$17.10
Operating profit per diluted share (TTM)
$3.42
EBITDA per diluted share (TTM)
$5.78
Net income per diluted share (TTM)
$2.05
Operating cash flow per diluted share (TTM)
$7.00
Free cash flow per diluted share (TTM)
$6.21
Capital expenditures per diluted share (TTM)
$0.79
R&D per diluted share (TTM)
$1.28
Stock compensation per diluted share (TTM)
$0.73
Book value per share
$17.60

Growth

11 metrics
Revenue growth YoY
+5.6%
Year over year
Net income growth YoY
-3.0%
Revenue (TTM)
$1.35B
Trailing 12 months
EPS growth YoY
+2.9%
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+4.5%
Revenue CAGR (5Y)
+8.9%
EPS CAGR (3Y)
-2.9%
EPS CAGR (5Y)
+5.8%
FCF CAGR (3Y)
+47.2%
FCF CAGR (5Y)
+29.4%

Quality

14 metrics
Return on equity
11.5%
Return on assets
4.1%
Debt / equity
1.4
Current ratio
3.1
EBITDA (TTM)
$270.39M
Free cash flow (TTM)
$291.22M
Quick ratio
1.9
Interest coverage
—
Net debt / EBITDA
3.5
Return on invested capital
6.6%
Trailing 12 months
Net cash
−$950.77M
Latest balance sheet
Cash & equivalents
$223.38M
Total assets
$2.37B
Total debt
$1.17B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$328.15M
Capital expenditures (TTM)
$36.93M
R&D (TTM)
$59.70M
SG&A (TTM)
$450.64M
Stock compensation (TTM)
$33.83M
R&D / revenue
4.4%
Stock compensation / revenue
2.5%

Ownership (13F)

9 metrics
13F filers
332
13F filer change QoQ
+8
Institutional ownership
110.1%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.3%
Holder tenure
15.4
Price vs estimated holder cost
+10.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.8%

Short interest

3 metrics
Short interest
7.5%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 313143 CUSIP 405024100 13F (30d) 53 filings 53 filers Visit website Investor relations